Ahead of an FDA advisory committee meeting, the agency is questioning the efficacy of Capricor’s Duchenne muscular dystrophy cell therapy deramiocel. The FDA’s briefing indicates the company did not meet trial objectives, setting up a high-stakes review of the evidence package for the therapy’s benefit in a disease where approval has been difficult to sustain with robust endpoints.